A Prospective, Randomized, Crossover-Design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis.

Trial Profile

A Prospective, Randomized, Crossover-Design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2015

At a glance

  • Drugs Daptomycin (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 16 Sep 2011 Actual patient no is 16 and trial phase changed from I to II as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top